Ask your healthcare provider if PAXLOVID or MOLNUPIRAVIR is right for you. Our team of healthcare professionals offers innovative healthcare solutions in the fight against COVID-19.
The FDA issued Emergency Use Authorization (EUA) for two oral treatments for COVID-19. The new treatment solution provides high-risk patients with an oral antiviral medication to reduce the likelihood of hospitalization and death. The pill requires a prescription issued by an authorized medical provider.
According to the FDA, the authorization of the pill is “a major step forward in the fight against this global pandemic.”
The Emergent clinics offer the pill as part of our comprehensive COVID-19 interventions, including vaccines and testing. Contact EmergentNOW or Emergent Testing to schedule an appointment.
Pfizer’s PAXLOVID received EUA approval for use in COVID-19 positive patients ages 12 and up with a high risk for progression to severe COVID-19. The PAXLOVID prescription includes nirmatrelvir and ritonavir tablets, which must be co-administered.
To achieve the best outcome, start treatment as soon as possible after a positive diagnosis and within five days of the start of symptoms. PAXLOVID may cause drug interactions with certain other medications.
Merck’s MOLNUPIRAVIR also received EUA approval for use in COVID-19 positive patients ages 18 and up with a high risk for progression to severe COVID-19. This solution applies when alternative COVID-19 treatment is not accessible or clinically appropriate.
To achieve the best outcome, start treatment as soon as possible after a positive diagnosis and within five days of the start of symptoms. Based on current and limited data, no drug interactions have been identified.
Currently, both COVID-19 pills are only available for patients at risk for severe illness from the virus. Also, only patients with a positive COVID-19 test and within the first five days of illness should receive a prescription for treatment.
MOLNUPIRAVIR has EUA approval for patients ages 18 and over, while PAXLOVID has EUA approval for patients ages 12 and over.
No. Neither pill has approval as a treatment to prevent infections after exposure to COVID-19. The treatment works to fight severe illness in high-risk patients diagnosed with COVID-19.
Yes. Both pills show positive results fighting various COVID-19 variants.
No. The COVID-19 vaccine remains effective in preventing COVID-19 for patients ages five and up. The new oral treatment solution reduces the risk of severe COVID-19 in high-risk patients and does not prevent the spread of COVID-19.
© 2022 EmergentTesting. All Rights Reserved.
